Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

Registrati

Quotazioni in diretta

MNKD MannKind Corporation

6,945

0,045 (0,65%)

Ultimo aggiornamento: 16:58:56

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/29/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Michael Edward Castagna

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni MannKind (NASDAQ:MNKD)
Storico
Da Ott 2024 a Nov 2024

Clicca qui per i Grafici di MannKind

Grafico Azioni MannKind (NASDAQ:MNKD)
Storico
Da Nov 2023 a Nov 2024

Clicca qui per i Grafici di MannKind

Notizie MannKind Corporation - MNKD

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 20 Novembre 2024 (3 giorni fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Venerdì 15 Novembre 2024 (7 giorni fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sabatp 9 Novembre 2024 (2 settimane fa) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Giovedì 7 Novembre 2024 (2 settimane fa) • Edgar (US Regulatory)

Form 8-K - Current report
Giovedì 7 Novembre 2024 (2 settimane fa) • Edgar (US Regulatory)

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
Giovedì 7 Novembre 2024 (2 settimane fa) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Mercoledì 6 Novembre 2024 (2 settimane fa) • Edgar (US Regulatory)

MannKind to Present at 2024 UBS Healthcare Conference
Martedì 5 Novembre 2024 (2 settimane fa) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Martedì 5 Novembre 2024 (3 settimane fa) • Edgar (US Regulatory)

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
Lunedì 4 Novembre 2024 (3 settimane fa) • GlobeNewswire Inc.

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
Giovedì 31 Ottobre 2024 (3 settimane fa) • GlobeNewswire Inc.

More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
Lunedì 30 Settembre 2024 (2 mesi fa) • GlobeNewswire Inc.

Più MannKind Corporation Articoli Notizie

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea